Li et al. reported that METTL3 was highly expressed in CRC metastatic tissues, and its knockdown inhibited tumor progression through an m6A- SRY (sex determining region Y)-box 2 (SOX2)-insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)-dependent mechanism [14]. The gene discussed is METTL3; the disease is neoplasm.